DD · DuPont de Nemours, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
DuPont raised full-year 2026 guidance to net sales of about $7.19 billion, operating EBITDA of $1.785 billion and adjusted EPS of $7.50, after third-quarter organic growth of 5%, adjusted EPS growth of 31% and margin expansion of 90 basis points.
DuPont posted third-quarter 2026 net sales of $1,868 million, up 4%, adjusted EPS of $2.09 and operating EBITDA of $469 million. It raised full-year 2026 adjusted EPS guidance to $7.47 - $7.52 per share and plans a $250 million fourth-quarter share repurchase.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Nov 3, 2026TL;DR. DuPont exceeded third-quarter guidance, delivered 5% organic sales growth, expanded operating EBITDA margin, posted substantially higher adjusted EPS, and generated strong cash conversion before raising full-year guidance again. Middle East project delays, currency and inflation headwinds, lower quarterly free cash flow, construction and automotive declines, and PFAS-related risks remain concerns.
- + Full-year 2026 guidance was raised again, with organic growth, operating EBITDA, and adjusted EPS all at or above the previous range’s high end.
- + DuPont completed a $250 million accelerated share repurchase, substantially completed $100 million of open-market purchases, and plans another $250 million repurchase in the fourth quarter.
- + The order book increased double digits year over year, supported by customer wins in adhesives, aerospace seals, and desalination.
- − Large Middle East water projects are expected to shift into 2027, and approximately $15 million of revenue was pushed out of the 2026 plan.
- − Currency reduced consolidated third-quarter sales growth by 1%.
- − Third-quarter transaction-adjusted free cash flow declined 1% year over year.
- − Oil and gas inflation created a margin headwind, partly offsetting growth and productivity benefits.
- − Construction and automotive end markets declined by low single digits, creating a headwind to portfolio growth.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted earnings (non-GAAP) non-GAAP | $483M | Six Months Ended Jun 30, 2026 | — |
| Adjusted EPS non-GAAP | $1.88 | second quarter 2026 | — |
| Adjusted free cash flow (non-GAAP) non-GAAP | $454M | Six Months Ended Jun 30, 2026 | — |
| Adjusted free cash flow conversion (non-GAAP) non-GAAP | 94% | Six Months Ended Jun 30, 2026 | — |
| Average price per share under Q2 2026 ASR Transaction | $148.91 | Q2 2026 ASR Transaction (completed May 2026) filing | — |
| Corporate operating EBITDA | -$53M | Six Months Ended Jun 30, 2026 | — |
| Diversified Industrials operating EBITDA | $413M | Six Months Ended Jun 30, 2026 | — |
| Healthcare & Water Technologies operating EBITDA | $502M | Six Months Ended Jun 30, 2026 | — |
| Operating EBITDA (non-GAAP) non-GAAP | $862M | Six Months Ended Jun 30, 2026 | — |
| Operating EBITDA margin non-GAAP | 24.6% | second quarter 2026 | — |
| Organic sales - Healthcare & Water Technologies | 3% | Six Months Ended June 30, 2026 | — |
| Organic sales growth non-GAAP | 4% | second quarter 2026 | — |
| Organic sales growth (Diversified Industrials) non-GAAP | 3% | 2Q'26 | — |
| Shares delivered under Q2 2026 ASR Transaction | 1.8M | Q2 2026 ASR Transaction (completed May 2026) filing | — |
| Total segment operating EBITDA | 471M | the three months ended June 30, 2026 filing | — |
| Transaction-adjusted free cash flow (non-GAAP) non-GAAP | $473M | Six Months Ended Jun 30, 2026 | — |
| Transaction-adjusted free cash flow conversion (non-GAAP) non-GAAP | 98% | Six Months Ended Jun 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Specialty Chemicals — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DD
this stock
DuPont de Nemours, Inc.
|
$20.38B | — | -7.1% | 69.0 | 2.9% |
|
LIN
Linde PLC
|
$241.51B | +23.4% | +3.0% | 34.9 | 1.4% |
|
AIQUF
L Air Liquide SA
|
$137.11B | +14.4% | — | — | 0.0% |
|
ECL
Ecolab Inc.
|
$86.74B | +17.8% | +2.2% | 42.1 | 1.5% |
|
SHW
Sherwin Williams Co
|
$84.53B | +8.0% | +2.1% | 32.2 | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 3, 2026
- This year
- 21
DuPont posted third-quarter 2026 net sales of $1,868 million, up 4%, adjusted EPS of $2.09 and operating EBITDA of $469 million. It raised full-year 2026 adjusted EPS guidance to $7.47 - $7.52 per share and plans a $250 million fourth-quarter share repurchase.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DD | +5.0% | +17.9% | +3.6% | +9.8% | +27.5% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +2.4% | +19.0% | +3.1% | +10.0% | +16.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.